Education and Training
ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
The purpose of this enhanced surveillance study ("ESS") is to collect information regarding chronic adverse events that are possibly related to the ExAblate® System ("ExAblate") that are received by InSightec ("InSightec") following PMA approval. This study will examine adverse events reported in patients undergoing the device procedure for the first two years of commercial experience. Other relevant data may be collected as well.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)
Eligibility
This study collects safety data on patient treatments performed commercially under the FDA
approved labeling.
- Eligibility is as per approved device indication.
- All registry-consented patients who undergo commercial ExAblate procedure for bone
mets palliation after device approval.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting